Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
MWN-AI** Summary
Aclarion, Inc., a healthcare technology company focused on enhancing chronic low back pain management, has announced a strategic partnership with Source Healthcare, an orthopedic clinic in Los Angeles. This collaboration aims to broaden the availability of Aclarion's Nociscan, a non-invasive diagnostic tool that assesses spinal disc pain using Magnetic Resonance Spectroscopy (MRS) and augments traditional MRI capabilities. By integrating Nociscan into Source Healthcare’s practice, led by Dr. Timothy T. Davis, the company seeks to strengthen its clinical validation and generate real-world evidence contrasting Nociscan with traditional anesthetic discography.
Nociscan offers a significant advantage as it objectively measures pain and structural integrity biomarkers associated with spinal discs without the invasiveness of spinal injections. This partnership aligns with Aclarion’s scalable growth strategy while enhancing the empirical data required for payer and provider adoption. The focal point will be to build a robust evidence base highlighting Nociscan's efficacy, particularly in the expansive pain management landscape, which has historically relied on more invasive procedures.
Ryan Bond, Chief Strategy Officer of Aclarion, noted that Nociscan has previously demonstrated improved outcomes and cost reductions in spinal fusion markets. By expanding its application to pain management, the partnership with Source Healthcare represents a meaningful step toward establishing vital clinical evidence for this innovative technology. Chronic low back pain remains a pressing global health issue, affecting millions, and Aclarion's objective is to facilitate more effective treatments.
With Nociscan's ability to provide clarity in diagnosing disc-derived pain, Aclarion continues to position itself as a leader in non-invasive pain management solutions, thereby enhancing patient care and potentially transforming treatment pathways in managing spinal pain.
MWN-AI** Analysis
Aclarion, Inc.'s recent partnership with Source Healthcare presents a significant market opportunity that investors should closely monitor. By integrating its Nociscan technology into a high-volume clinical practice in Los Angeles, Aclarion is well-positioned to enhance its presence in the growing chronic low back pain (cLBP) market, which impacts millions globally.
The transition from traditional anesthetic discography to Nociscan’s non-invasive approach underscores a potentially transformative shift in pain management. With clinical validation supporting Nociscan's effectiveness, this partnership not only reinforces the product's credibility but also opens pathways to real-world evidence generation essential for payer and provider adoption. Investors should recognize the strategic advantage of Nociscan’s ability to deliver objective pain assessments, potentially leading to better patient outcomes and reduced healthcare costs.
Moreover, the expected generation of real-world evidence comparing Nociscan with established procedures is a crucial metric. As studies show a 97% surgical success rate when targeting Nociscan-positive discs, Aclarion could see increased demand from both healthcare providers and insurers, possibly resulting in a formidable competitive edge.
Looking ahead, this synergistic collaboration aligns with Aclarion's scalable growth strategy. Investors should keep an eye on the expansion of Nociscan into additional markets beyond Los Angeles. As the platform proves its effectiveness through enhanced clinical pathways, broader adoption could drive significant revenue growth.
Given these developments, Aclarion’s stock (Nasdaq: ACON) could become an attractive inclusion in portfolios focused on healthcare technology and innovative pain management solutions. However, potential investors should also be cautious of market volatility and conduct due diligence regarding the risks outlined in the company’s SEC filings.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Expands availability of Nociscan in the greater Los Angeles area
- Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
- Supports scalable growth strategy while building data assets critical to payer and provider adoption
BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Healthcare, a state-of-the-art orthopedic and regenerative health clinic in Los Angeles to help address a key gap in addressing low back pain.
The agreement aligns with Aclarion’s expansion strategy by bringing Nociscan to Source Healthcare and the multidisciplinary team led by interventional pain management specialist, Timothy T. Davis, MD. Moreover, the growing evidence base for Nociscan will be strengthened by adding a high-volume clinical practice where real-world evidence comparing Nociscan and anesthetic discography will be generated. An anesthetic discogram is a diagnostic spinal injection procedure used to identify specific spinal disc(s) causing chronic pain. Nociscan is a non-invasive alternative that objectively measures pain and structural integrity biomarkers in spinal discs through an MRI-like experience for the patient.
“Our team at Source Healthcare emphasize holistic-care and science backed solutions for pain relief of those suffering from spine and chronic pain,” said Tim Davis, MD, interventional pain management specialist and founder of Source Healthcare. “We see and treat a lot of patients with chronic low back pain and degenerative disc disease. Historically, we have used lumbar MRI and anesthetic discography with good results. We are excited to gain access to Nociscan, a MR Spectroscopy test that objectively evaluates various pain and structural integrity biomarkers non-invasively, something not available from MRI or discography. We believe this test will become a valuable part of our care pathways.”
“Nociscan has demonstrated improved outcomes and lower costs in peer-reviewed published literature when studied in the spinal fusion market. This study is our first opportunity to establish evidence within the much larger pain management field,” stated Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to be working with Dr. Davis, a true leader in the field of Pain Management, on this seminal real-world evidence work.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
FAQ**
How will Aclarion Inc. Warrant ACONW influence the financial resources available for expanding Nociscan's availability in the greater Los Angeles area?
What specific metrics will Aclarion use to track the effectiveness of Nociscan compared to anesthetic discography at Source Healthcare in LA?
How does Aclarion plan to leverage real-world clinical validation from Source Healthcare to enhance the adoption of Nociscan and its associated technology?
What role does Aclarion Inc. Warrant ACONW play in the company's strategy for scaling up its operations and expanding its clinical data assets in the pain management sector?
**MWN-AI FAQ is based on asking OpenAI questions about Aclarion Inc. (NASDAQ: ACON).
NASDAQ: ACON
ACON Trading
2.34% G/L:
$3.065 Last:
7,177 Volume:
$2.98 Open:
